Share this video  

VJHemOnc is committed to improving our service to you

ASH 2018 | Is CLL chemoimmunotherapy finished?

Robin Foà
ASH 2018
Chronic Lymphocytic Leukemia Leukemia Bendamustine Ibrutinib Rituximab

Robin Foà, MD, of Sapienza University of Rome, Rome, Italy, gives us his take on the key chronic lymphocytic leukemia (CLL) highlights from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Prof. Foà highlights novel agents changing the treatment landscape.

More from Robin Foà

6:16
25-month follow-up on GIMEMA LAL2116: D-ALBA induction in ALL
Robin Foà • 14 Jun 2021
2:34
Exploring chemotherapy-free induction treatment for patients with Ph+ ALL
Robin Foà • 11 Jun 2022
6:28
Prognostic markers and MRD in CLL
Robin Foà • 25 Oct 2018
3:16
Clinical approaches in Ph+ and Ph-like ALL
Robin Foà

Related Videos

1:41
Key challenges of using the intestinal microbiome as a biomarker
Melody Smith
1:32
CAR T-cell therapy: the importance of LTFU
Graham Collins
1:44
The future of AML therapy
Andreas Burchert
0:42
Treating pediatric patients with hematological malignancies
Claudia Rössig
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals